1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol.,2017
2. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts;Fry;Mol. Cancer Ther.,2001
3. U.S. Food and Drug Administration, Full prescribing information: IBRANCE (palbociclib) capsules, for oral use, Initial U.S. Approval: 2015, 2019, 〈https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf〉, accessed 25 April 2022.
4. European Medicines Agency, ANNEX I (Ibrance): Summary of product characteristics, 2016, 〈https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf〉, accessed 25 April 2022.
5. Palbociclib and letrozole in advanced breast cancer;Finn;N. Engl. J. Med.,2016